Skip to content

Study · Observational study · n = 73,636 · 2025

5 results

Blinded by the drug? A vigilyze signal linking semaglutide to NAION.

Suresh J, Vivekanandan K

International ophthalmology30 Sept 2025Cited by 3 (Europe PMC)

PMID41026313 (opens in a new tab)DOI10.1007/s10792-025-03760-7 (opens in a new tab)PepBankPUB-41026313
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studySafety outcome

    In VigiBase, 91 of 73,636 individual case safety reports for semaglutide named non-arteritic anterior ischemic optic neuropathy (NAION).

    In plain wordsIn a global drug safety database, 91 of 73,636 semaglutide reports described a sudden eye nerve condition called NAION.

    Peptide
    Semaglutide
    Outcome
    Not applicableNAION reports among semaglutide case reports
    Study

    n = 73,636

    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated

    Measurements

    NAION case reports
    91 reports
    semaglutide ICSRs

    Source sentences

    Summary
    Of 73,636 global Individual Case Safety Reports (ICSRs) related to Semaglutide reported adverse reactions globally, 91 were associated with the adverse reaction NAION.
    1 context sentence
    Summary · context
    A retrospective, post-market observational study was conducted using data collected from VigiBase® until June 2025, using mapped terms under Medical Dictionary for Regulatory Activities (MedDRA).
  2. 02HumanObservational studySafety outcome

    Among the NAION cases, Denmark reported the most (38 cases, 41.80%), then Australia (9, 9.90%) and France (7, 7.70%).

    In plain wordsMost of the NAION reports came from Denmark, then Australia and France.

    Peptide
    Semaglutide
    Outcome
    Not applicableCountries reporting NAION cases
    Study

    n = 91

    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated

    Measurements

    Denmark cases
    38 cases
    NAION reports
    Australia cases
    9 cases
    NAION reports
    France cases
    7 cases
    NAION reports

    Source sentences

    Summary
    The cases were reported globally with increased number of cases reported by Denmark (N = 38, 41.80%), Australia (N = 9, 9.90%) and France (N = 7, 7.70%)
    1 context sentence
    Summary · context
    A retrospective, post-market observational study was conducted using data collected from VigiBase® until June 2025, using mapped terms under Medical Dictionary for Regulatory Activities (MedDRA).
  3. 03HumanObservational studySafety outcome

    The NAION reports mainly concerned patients aged 45-74 years (50 cases, 54.90%).

    In plain wordsMost NAION reports were for people aged 45 to 74 years.

    Peptide
    Semaglutide
    Outcome
    Not applicableAge of patients with NAION reports
    Study

    n = 91

    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated

    Measurements

    Patients aged 45-74 years
    50 cases
    NAION reports

    Source sentences

    Summary
    primarily affected patients aged 45-74 years (N = 50, 54.90%).
    1 context sentence
    Summary · context
    A retrospective, post-market observational study was conducted using data collected from VigiBase® until June 2025, using mapped terms under Medical Dictionary for Regulatory Activities (MedDRA).
  4. 04HumanObservational studySafety outcome

    Most NAION cases (97.80%) were classified as serious.

    In plain wordsAlmost all of the NAION reports (97.80%) were classed as serious.

    Peptide
    Semaglutide
    Outcome
    Not applicableSeriousness of NAION reports
    Study

    n = 91

    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated

    Measurements

    Serious cases
    97.8%
    NAION reports

    Source sentences

    Summary
    Most cases (97.80%) were classified as serious with a significant of the cases reported of males.
    1 context sentence
    Summary · context
    A retrospective, post-market observational study was conducted using data collected from VigiBase® until June 2025, using mapped terms under Medical Dictionary for Regulatory Activities (MedDRA).
  5. 05HumanObservational studySafety outcome

    Co-reported serious eye conditions included visual impairment, blindness (9.90%), visual field defect (5.50%), optic atrophy (4.40%) and blurred vision (4.40%).

    In plain wordsReports of NAION often also named other serious eye problems such as visual impairment and blindness.

    Peptide
    Semaglutide
    Outcome
    Not applicableCo-reported eye reactions with NAION
    Study

    n = 91

    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated

    Measurements

    Blindness
    9 cases
    NAION reports
    Visual field defect
    5 cases
    NAION reports
    Optic atrophy
    4 cases
    NAION reports
    Vision blurred
    4 cases
    NAION reports

    Source sentences

    Summary
    The co-reported reactions involved serious 'eye-related' conditions like Visual Impairment (N = 12,13.20%), Blindness (N = 9, 9.90%), Visual field defect (N = 5, 5.50%), Optic atrophy (N = 4, 4.40%), Vision blurred (N = 4, 4.40%) among other serious reactions.
    1 context sentence
    Summary · context
    A retrospective, post-market observational study was conducted using data collected from VigiBase® until June 2025, using mapped terms under Medical Dictionary for Regulatory Activities (MedDRA).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.